Advances in Postoperative Adjuvant Therapy for Squamous
Esophageal Cancer

Min Zhu; Jinlin Liu; Simin Tan; Xuefeng Luo; Hai Zeng*

doi:10.70711/pmr.v2i5.6716

Advances in Postoperative Adjuvant Therapy for Squamous Esophageal Cancer

Min Zhu, Jinlin Liu, Simin Tan, Xuefeng Luo, Hai Zeng*

Abstract

Esophageal cancer is a common malignancy worldwide with a 5-year survival rate of less than 40%. Surgical resection is the treatment of choice for esophageal squamous carcinoma (ESCC) as the main pathological type, but postoperative adjuvant therapy for locally
advanced patients is crucial to improve survival and local control. This article reviews the current status of postoperative adjuvant therapy for
esophageal squamous carcinoma, including adjuvant chemotherapy, radiotherapy, simultaneous radiotherapy, chemotherapy and immunotherapy, and discusses future research directions.

Keywords

Squamous esophageal cancer; Postoperative adjuvant; Immunotherapy

Full Text:

PDF

Included Database

References

[1] XIAO Zefen, YANG Zongyi, WANG Luhua, et al. Impact of postoperative lymph node metastasis of esophageal cancer on survival and

significance of radiation therapy[J]. Chinese Journal of Tumors, 2004, 26(2): 112-115.

[2] WEISS J A, JAIN S. Neoadjuvant and adjuvant therapy in esophageal cancer[J]. J Gastrointest Oncol, 2023, 14(4): 1927-1932.

[3] UHLENHOPP D J, THEN E O, SUNKARA T, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk

factors[J]. Clin J Gastroenterol, 2020, 13(6): 1010-1021.

[4] CSONTOS A, FAZEKAS A, SZAKO L, et al. Effects of neoadjuvant chemotherapy vs chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis[J]. World J Gastroenterol, 2024, 30(11): 1621-1635.

[5] PENNATHUR A, GIBSON M K, JOBE B A, et al. Oesophageal carcinoma[J]. Lancet, 2013, 381(9864): 400-412.

[6] JIN Z, CHEN D, CHEN M, et al. (Neo)adjuvant Chemoradiotherapy is Beneficial to the Long-term Survival of Locally Advanced Esophageal Squamous Cell Carcinoma: A Network Meta-analysis[J]. World J Surg, 2022, 46(1): 136-146.

[7] ANDO N, IIZUKA T, IDE H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of

the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204[J]. J Clin Oncol, 2003, 21(24): 4592-4596.

[8] HUANG B, CHAN E G, PENNATHUR A, et al. The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB

analysis[J]. BMC Cancer, 2021, 21(1): 1334.

[9] DENG X, HE W, JIANG Y, et al. The impact of adjuvant therapy on survival for node-negative esophageal squamous cell carcinoma: a

propensity score-matched analysis[J]. Ann Transl Med, 2021, 9(12): 998.

[10] YU S, ZHANG W, NI W, et al. A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative

treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy[J]. Radiother Oncol,

2019, 140: 159-166.

[11] LIN H, CHEN L, SHANG Q, et al. A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma[J]. Int J Surg, 2020, 80: 184-191.

[12] SUN J. Adjuvant Therapy for Esophageal Squamous Cell Carcinoma[J]. Korean J Thorac Cardiovasc Surg, 2020, 53(4): 168-171.

[13] van HAGEN P, HULSHOF M C C M, van LANSCHOT J J B, et al. Preoperative chemoradiotherapy for esophageal or junctional

cancer[J]. N Engl J Med, 2012, 366(22): 2074-2084.

[14] AJANI J A, D'AMICO T A, BENTREM D J, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical

Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2023, 21(4): 393-422.

[15] KATO K, KOJIMA T, HARA H, et al. First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year

extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study[J]. Esophagus, 2024, 21(3): 306-318.

[16] PARK S, SUN J, CHOI Y, et al. Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a

placebo-controlled, randomized, double-blind, phase II study[J]. randomized, double-blind, phase II study[J]. ESMO Open, 2022, 7(1):

100385.

[17] XIE X, ZHANG H, HE H, et al. Postoperative adjuvant immunotherapy for pathological stage II-IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates[J]. Front Med (Lausanne), 2024, 11: 1517001.

[18] MATSUBARA T, YAMAGUCHI M, SHIMOKAWA M, et al. Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with

Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial[J]. Clin Lung Cancer, 2024, 25(3): 280-283.

DOI: http://dx.doi.org/10.70711/pmr.v2i5.6716

Refbacks

There are currently no refbacks.